MHRA Explains Interim Plans For Granting UK-Wide Approvals Until 2025
Executive Summary
As part of post-Brexit arrangements to make sure new drugs are made available to people in all four countries of the UK, an interim mechanism has been set up for when a product is approved in the UK before the EU.